Author:
Liossis Stamatis Nick,Staveri Chrysanthi
Abstract
Systemic lupus erythematosus (SLE) is a chronic autoimmune multisystem disease with a variable presentation and manifestations ranging from mild to severe or even life-threatening. There is an ongoing and unmet need for novel, disease-specific, effective and safe treatment modalities. The aim of this review is to summarize data on SLE treatment that have emerged over the last 3 years. We will put emphasis on studies evaluating potential treatments on severe lupus manifestations such as lupus nephritis. Despite the existence of several therapeutic agents in SLE, the disease keeps causing significant morbidity. It is encouraging that a variety of therapeutic options are currently under investigation, although there are occasional trial failures.
Reference79 articles.
1. Lupus: an overview of the disease and management options;Maidhof;PT.,2012
2. B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events;Liossis;J Clin Invest.,1996
3. Rituximab for SLE refractory to conventional treatment: results of a cohort evaluating efficacy and long-term outcome;Staveri;Clin Exp Rheumatol.,2016
4. B cell-based treatments in SLE: past experience and current directions;Liossis;Curr Rheumatol Rep.,2017
5. Murine lupus in the absence of alpha beta T cells;Peng;J Immunol.,1996
Cited by
32 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献